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Fetal Medicine Foundation (FMF) algorithm. Both NICE and ACOG guidelines use maternal demographics 
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of the available medical literature was performed using the search engines MEDLINE- PubMed, Google 
Scholar, and Science of Web. Keywords included: “Preeclampsia” AND “NICE guidelines" AND "fetal 
medicine foundation" and “Preeclampsia screening guidelines”. The GRADE Working Group was used to 
assess the quality of relevant studies. Results: During the search, 2 articles were found to meet the 
eligibility criteria. Both were prospective multicenter cohort studies. Conclusion: The FMF algorithm which 
combines maternal factors with biophysical and biochemical markers is superior in screening for 
preeclampsia during weeks 11-13 gestation compared to the NICE algorithm. The quality of evidence is at 
a low to very low due to risk of publication bias and incomplete blinding. 
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Abstract  
Background: 
Approximately 3% of pregnant women develop preeclampsia at some time during their 
pregnancy. Preeclampsia is a common cause of maternal and fetal morbidity and mortality 
worldwide. Currently there are 3 assessment tools for preeclampsia: the National Institute for 
Health and Care Excellence (NICE) guidelines, the American College of Obstetricians and 
Gynecologist (ACOG) and the Fetal Medicine Foundation (FMF) algorithm. Both NICE and 
ACOG guidelines use maternal demographics and medical history as a screening tool. The more 
recent approach, FMF uses Bayes theorem utilizes biophysical and biochemical markers in 
addition to maternal risk factors.  
 
Methods:  An exhaustive search of the available medical literature was performed using the 
search engines MEDLINE- PubMed, Google Scholar, and Science of Web. Keywords included: 
“Preeclampsia” AND “NICE guidelines" AND "fetal medicine foundation" and “Preeclampsia 
screening guidelines”. The GRADE Working Group was used to assess the quality of relevant 
studies.  
  
Results: During the search, 2 articles were found to meet the eligibility criteria. Both were 
prospective multicenter cohort studies.  
 
Conclusion: The FMF algorithm which combines maternal factors with biophysical and 
biochemical markers is superior in screening for preeclampsia during weeks 11-13 gestation 
compared to the NICE algorithm. The quality of evidence is at a low to very low due to risk of 
publication bias and incomplete blinding.  
  
Keywords:  First trimester screening, preeclampsia, NICE algorithm, FMF algorithm, mean 
arterial pressure, placental growth factor, pregnancy associated plasma protein A, uterine artery 
Doppler 
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Comparison of FMF with NICE and ACOG Algorithm in Early Preeclampsia 
Screening at 11-13 Weeks Gestation 
BACKGROUND 
      Preeclampsia is a complication of pregnancy that is characterized by high blood pressure 
with signs of end organ damage especially the liver and kidney. Despite intense years of research 
over the years the etiology of preeclampsia remains unknown.1 According to the American 
College of Obstetrics and Gynecologists Preeclampsia is defined as blood pressure greater than 
140/90 mmHg on two occasions, at least four hours apart and proteinuria (greater than 300mg 
per 24hr urine collection or +1 on a dipstick or protein/creatinine ratio greater than or equal to 
0.3) in pregnant women who were previously normotensive. In the absences of proteinuria, a 
new onset of hypertension with a presence of one of the following: thrombocytopenia, renal 
insufficiency, impaired liver function, pulmonary edema or cerebral/visual disturbance will meet 
diagnostic criteria. Preeclampsia occur as early as 20 weeks of pregnancy and can last up to six 
weeks into the postpartum period.2 
     Despite extensive research and advance in the field of medicine preeclampsia remains the 
leading cause of mortality and morbidity worldwide resulting in thousands of  death of both the 
mother and fetus every year.2 Over the last decade many studies have been conducted in an effort 
to find a better screening tool to reduce the disease prevalence by initiating pharmacological 
intervention for those at high risk3 and minimize the adverse events in those who are already 
experiencing preeclampsia by planning delivery in timely manner at appropriate facility.4  The 
general approach, based on the National Institute for Health and Care Excellence (NICE) and the 
American College of Obstetricians and Gynecologists (ACOG) recommendation has been to 
identify risk based on maternal demographics and medical history as a way to screen for 
preeclampsia, whereas Fetal Maternal Foundation (FMF) approach utilizes biophysical and 
biochemical markers in addition to prior maternal risk factors.5  
    The NICE guideline uses maternal risk factors such as history of hypertensive disease in 
previous pregnancy, chronic kidney disease, autoimmune disease, diabetes mellitus and chronic 
hypertension, first pregnancy, age ≥ 40 years, interpregnancy interval > 10 years, body mass 
index (BMI) at first visit of ≥ 35 kg/m2 or family history of preeclampsia to determine the risk of 
developing preeclampsia. Whereas according to ACOG nulliparity, age > 40 years, BMI ≥ 30 
kg/m2, in-vitro fertilization, history of previous pregnancy complicated by PE, family history of 
PE, chronic hypertension, chronic renal disease, diabetes mellitus, systemic lupus erythematosus 
or thrombophilia are all considered maternal risk factors for developing PE. In addition to 
maternal risk factors the FMF screening model utilizes Mean Arterial Pressure (MAP), serum 
pregnancy associated plasma protein-A (PAPP-A), Uterine artery pulsatility index (UtA-PI) and 
serum placental growth factor (PlGF) to determine women who are at high risk for developing 
PE. The goal of this review is to determine whether NICE guideline or FMF algorithm is 
superior in detecting risk of developing preeclampsia early in the pregnancy.5   
METHODS 
    After an extensive search using MEDLINE- PubMed, Google Scholar, and Science of Web 
articles were narrowed down using the search phrase “Preeclampsia AND "NICE guidelines" 
AND "fetal medicine foundation". Eligible studies included English language articles, 
comparison of FMF algorithm to NICE and/or ACOG algorithm, screened during the first 
trimester, large population size, and documented statistical analysis. Studies failing to compare 
the FMF screening tool with the current NICE guidelines, screening taking place in the second or 
third trimester, and studies focusing on therapy were excluded. The qualities of the eligible 
articles were evaluated using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group guidelines.6   
 
RESULTS 
    The initial search using MEDLINE- PubMed revealed 3 articles to review. Using the 
eligibility criteria only 1 was found to be relevant.5 A search of Google Scholar resulted in 89 
articles. Only 2 meet the eligibility criteria5,7 One of the 2 included the same article by 
O’Gorman was found in MEDLINE- PubMed. The remaining 87 articles were excluded.  Web of 
Science resulted in zero results. In total 2 articles5,7 were analyzed for this systematic review. 
Both articles were prospective multicenter cohort studies. (See Table 1.) 
 
O’Gorman et al. (2017) 
    The purpose of this prospective multicenter study5 was to compare the new FMF algorithm 
with the current standard practice NICE and ACOG method to determine if one is superior in 
detecting preeclampsia early. This study included 8775 women who are 11-13 weeks gestation at 
12 maternity hospitals in 5 different countries. These countries were the UK, Spain, Belgium, 
Greece, and Italy. Patients were recruited between February and September 2015. These women 
completed a written informed consent to participate in the trial and were approved by National 
Health Service Research Ethics Committee in the UK.5  
    The detection rate (DR) was calculated for NICE, ACOG and FMF in every patient.5 NICE 
and ACOG DR was determined by inquiring medical history and maternal factors.8 Then each 
risk factor which was used as a separate screening test and added together to calculate the 
detection rate and positive screening rate. The results were viewed using statistical software 
package R. With the FMF algorithm, maternal factors were collected, MAP and UtA-PI were 
measured using standardized protocols9,10 and PAPP-A and PlGF concentrations were collected. 
The collected data were combined with the use of Bayes’ theorem to determine individual patient 
specific risks of PE.5  
    The results revealed that with the use of the FMF algorithm a detection rate of PE 100% at 
<32 weeks, 75% at <37 weeks, and 43% at > 37 weeks and a 10.0 % FPR.  The NICE algorithm 
detected 41% of PE <32 weeks, 39% of PE <37 weeks, and 34% of PE > 37 weeks. (See Table 
2.) In comparison, of the 2 algorithms for early screening, FMF is the more accurate screening in 
determining pregnancies at high risk for developing pre-eclampsia.5 Limitations of this study 
include failure to blind the patients and physicians, small population size that developed PE 
which lead to a wide confidence intervals, and publication bias due to funding by FMF.5   
 
Tan et al. (2018) 
    The prospective multicenter study7 compared the current screening method, NICE and ACOG, 
to the new algorithm FMF for detecting PE. There were 16 747 patients at 11-13 weeks gestation 
from seven different maternity hospitals who were recruited between April 2016 to December 
2016 to participate in the study. Inclusion criteria included age > 18 years, singleton pregnancy, 
and live fetus. Exclusion criteria were women who were unconscious or severely ill, had learning 
difficulties or serious mental illness, and major fetal abnormality at the 11-13 week scan.7 Each 
participant had to meet the inclusion criteria, sign a formed consent to agree to participate in the 
study, and receive approval from the London Surrey Borders Research Ethics Committee.7 
    Maternal characteristics as well as biomarkers including MAP, UtA-PI, PlGF, and PAPPA-A 
were obtained from each participant. Standardized protocols were used to measure MAP and 
UtA-PI to keep measurements consistent across the different participating hospitals.11,12 MAP 
was measured by either health care assistant or sonographers while the UtA PI was completed 
only by the sonographers. PAPP-A and PlGF were measured using either DELFIA Xpress 
analyzer or KRYPTOR analyzer. Quality control was used to make sure measured markers were 
consistent across the seven hospitals. The results were blinded to participants and their 
physicians. The measurements were sent to UCL-CCTU where the statisticians analyzed the data 
using both NICE and FMF algorithm as well as identifying those who were treated with aspirin 
and the association between aspirin and baseline results.7 
    The first comparison included mini combined test vs NICE algorithm. The mini combined test 
collected maternal factors, MAP, and PAPP-A and used Bayes’ theorem. The reason for 
including these specific biomarkers was due no extra cost associated with it. The second 
comparison used the NICE guidelines vs three subgroups of markers and Bayes’ theorem. These 
groups included maternal factors, MAP, and PAPP-A; maternal factors, MAP, and PlGF; and 
maternal factors, MAP, UtA-PI and PlGF. PlGF was selected because it has a better success rate 
than PAPPA-A marker in predicting PE in previous studies. The maternal factors, MAP, UtA-PI 
and PlGF was found to be the most accurate combination in detecting preterm PE in previous 
studies which is why it was also selected.7  
    The study found that using the combination of maternal factors and biomarkers were far more 
accurate in detecting PE when compared to the NICE guidelines. The NICE guidelines detected 
approximately 30% of pregnancies that would go on to develop PE and approximately 40% of 
pregnancies that would develop severe PE with a FPR of 10.0%.1 (See Table 2.) The FMF 
algorithm which included maternal factors, MAP, and serum PAPP-A detected 42.5% of all PE. 
The combination of maternal factors, MAP, UtA-PI and PlGF detected 82.4% of preterm PE 
with a FPR of 10.0%.7  
 
DISCUSSION 
    Undiagnosed preeclampsia can lead to very serious, even fatal, complications for both the 
mother and the fetus. It’s clear that a more accurate and sensitive screening tool is needed to 
identify pregnant women who are at risk for developing preeclampsia and plan intervention 
appropriately in order to decrease the mortality and morbidity related to preeclampsia. Analyzing 
the data from the 2 studies5,7 shows that using biophysical and biochemical markers in 
combination with pre-existing maternal risk factors is superior in detecting preeclampsia early on 
when compared to the traditional approach which only uses maternal risk factors. These 
additional measurements can be completed in the office during a routine visit at 11-13 weeks 
gestation. MAP measurement requires inexpensive equipment and minimal training of a health 
care assistant.5 Though it does require adherence to the appropriate protocol in order to obtain an 
accurate result.9 UtA-PI is measured by a sonographer and also requires adherence to protocol.10 
Each exam only takes a few minutes to perform. PlGF and PAPP-A which are found in the 
serum can be collected with routine labs during the initial visit. The additional labs can be 
completed using the same machine which is commonly used to test for free B-human chorionic 
gonadotropin.5 These measurements are put into the FMF risk assessment tool which then 
calculates the PE risk. The FMF risk assessment tool developed by FMF is available for free 
online at www.fetalmedicine.com.  
    Both studies5,7 that were reviewed concluded that the FMF screening tool was superior to the 
standard NICE and ACOG method in detecting PE during 11-13 weeks gestation. O’Gorman et 
al (2017) 5 detected in a population size of 8775 singleton pregnancies, 100% (95% CI, 80-
100%) of PE <32 weeks, 75% (95% CI, 62-85%) of PE < 37 weeks and 43% (95% CI, 35-50%) 
of PE > 37 weeks and a FPR of 10.0%2  with the use of FMF algorithm. Using the same 
population, NICE13 and ACOG14 guidelines were also applied. NICE screening detected 41% 
(95% CI, 18-67%) of PE <32 weeks, 39% (95% CI, 27-53%) of PE < 37 weeks, and 34% (95% 
CI, 27-41%) of PE >37 weeks at a 10.2% FPR. ACOG screening revealed 94% (95% CI, 71-
100%) of PE <32 weeks, 90% (95% CI, 79-96%) of PE < 37 weeks, and 89% (95% CI, 84-94%) 
of PE > 37 weeks at a 64.2% FPR. 
    Tan et al7 detected 31.5% (95% CI, 27.3-35.7%) of all PE and 40.8% (95% CI, 32.8-48.9%) of 
preterm PE via the NICE algorithm. Note the effect of aspirin used in some patients was 
adjusted. The FMF algorithm detected 42.5% (95% CI, 38.0-46.9%) of all PE. Screening for 
preterm PE via FMF screening tool revealed maternal factors, MAP and PAPP-A detected 53.5% 
(95% CI, 27.3-35.7%) of PE, maternal factors, MAP and PlGF detected 69.9% (95% CI, 61.4-
76.6%) of PE, and maternal factors, MAP, PlGF, and UtA-PI detected 82.4% (95% CI, 76.1-
88.7%) of PE. 
    The main limitations of the two studies was the fact that it was funded by FMF which can be 
considered biased. However, FMF is not benefiting financially from their screening tool as it is 
offered free for any health care provider via their website. One of the limitations of the study 
conducted by O’Gorman et al5 was the wide confidence intervals. This is due to the small 
number of patients who developed PE. However, O’Gorman et al5 noted these values and the 
results were similar to the data collected in an earlier study15 which included a larger population 
size of 35 948 participants. Other limitations of the O’Gorman et al study5 included the lack of 
blinding of the participants and their health care providers to the measurements and outcomes of 
the screening tools. 
    In general, the additional measurements to complete the FMF screening tool appears to be 
only require minimal additional training, equipment, time, and cost. However, no study has been 
conducted to assess these factors and the practicality of the additional measurements. It would be 
recommended to further study the potential cost to determine if it would be practical and 
beneficial to implement in the clinics. Also, it would be important to conduct studies that 
evaluate the early and accurate detection of high risk patients for PE using FMF algorithm would 
decrease morbidity and mortality in both mother and child.  
 
CONCLUSION 
    The FMF algorithm which combines maternal factors with biophysical and biochemical 
markers, MAP, UtA-PI and PIGF is superior in screening for preeclampsia during weeks 11-13 
gestation compared to the standard NICE guidelines. Based on current low to very low evidence 
available more studies are warranted. However FMF algorithm is a promising approach to 
screening for preeclampsia. Further study, assess the financial implication of implementing this 
algorithm into clinical practice is also necessary.   
 
 
 
 
 
 
 
 
 References 
 
1. Norris W, Nevers T, Sharma S, Kalkunte S. Review: hCG, Preeclampsia and Regulatory 
T cells. Placenta. 2011;32(Suppl 2):S182-S185. doi:10.1016/j.placenta.2011.01.009. 
2009;374:979-88. 
2. American College of Obstetricians and Gynecologists, eds. Hypertension in Pregnancy. 
Washington, DC: American College of Obstetricians and Gynecologists; 2013. 
3. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth 
restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 
2010;116:402-14 
4. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant 
monitoring for gestational hypertension or mild pre- eclampsia after 36 weeks 
gestation (HYPITAT): a multicentre, open-label randomised controlled trial. 
5. O’Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal 
factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG 
recommendations. Ultrasound in Obstetrics & Gynecology. 49(6):756-760. 
doi:10.1002/uog.17455. 
6. GRADE Working Group. Grading of recommendations assessment, development and 
evaluation. http://www.gradeworkinggroup.org/. 
7. Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening 
for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: 
results of SPREE. Ultrasound in Obstetrics & Gynecology. 51(6):743-750. 
doi:10.1002/uog.19039. 
8. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth 
factor in the three trimesters of pregnancy: effects of maternal characteristics and medical 
history. Ultrasound Obstet Gynecol 2015; 45:591 – 598. 
9. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement 
of mean arterial pressure at 11-13 weeks’ gestation. Fetal Diagn Ther 2012; 31: 42-48. 
10. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11+0 
to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30:742-749. 
11. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for 
measurement of mean arterial pressure at 11-13 weeks’ gestation. Fetal Diagn Ther 2012; 31: 42 
– 48. 17. 
12. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11+0 
to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30: 742–
749. 
13. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in 
Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG 
Press, 2010. 
14. ACOG. First-trimester risk assessment for early-onset preeclampsia. Committee opinion No. 
638. Obstet Gynecol 2015; 126: e25-27. 
15. O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides 
KH.    Competing risks model in screening for preeclampsia by maternal factors and biomarkers 
at11-13 weeks’ gestation. Am J Obstet Gynecol 2016; 214:103.e1-e12. 
 
 
 
Table 1: Quality Assessment of Reviewed Articles 
Study Design                                 Downgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision Publication 
bias 
O’Gorman 
et al5  
Prospective 
Cohort 
Not 
Seriousa 
Not Serious Not Serious Serious Likelyb Very 
Low 
Tan et al7 Prospective 
Cohort 
Not 
Seriousa,c 
Not Serious Not Serious Serious Likelyb Very 
Low 
a  Both studies had large sample sizes  
b  Both studies were funded by FMF and other agencies 
c Lack of blinding 
 
Table 2 Summary of Study Findings  
 
O’Gorman et al5 
Outcome NICE 
(n=8775) 
 FMF 
(n=8775) 
 ACOG 
(n=8775) 
DR of PE < 32 weeks of delivery 41% 
(95% CI, 27-53) 
  
100% 
(95% CI, 80-100) 
94% 
(95% CI, 71-100% 
DR of PE < 37 weeks of delivery 39% 
(95% CI, 27-53) 
75% 
(95% CI, 62-85) 
90% 
(95% CI, 79-96% 
DR of PE > 37 weeks of delivery 34% 
(95% CI, 27-41) 
43% 
(95% CI, 35-50) 
89% 
(95% CI, 84-94%) 
FPR 10.2% 10% 64.2% 
Tan et al7 
 
Outcome  NICE 
(n= 16747) 
Baye Theorem Based Method 
(n=16747) 
DR for all PE 30.4% 
( 95% CI, 26.3-34.6) 
42.5% 
(95% CI, 38.0-46.9) 
DR for preterm PE 40.8% 
(95% CI, 32.8-48.9) 
82.4% 
(95% CI, 76.1-88.7%) 
  
 
 
 
  
 
 
